- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Cohance Lifesciences' Q1FY27 revenue fell 23.1% to ₹422.3 Cr, with Adjusted EBITDA at ₹9.2 Cr. Management projects H2 growth driven by secured orders, new product deliveries, and pipeline progress. Strategic focus includes integrating nucleic-acid business and repositioning Agrochemicals.